I confess in the days when I watched TV if I was short on inspiration then I’d check out the TV guide in a newspaper to see what they recommended for the evening’s viewing.

Such guides are by definition, the eclectic, subjective choice of the reviewer and they are designed to showcase programs catching their interest and, in the process, persuade you to see something you might otherwise not have watched.

This post is written in the same spirit.

For the past several years now we’ve been writing about the potential of harnessing the unique properties of Natural Killer (NK) cells for cancer immunotherapy and even produced a podcast episode on it back in 2018!

Since the publication of a landmark NEJM paper on CAR modified NK cells in 2020, we’ve seen even more interest flourish in the field.

This year’s annual meeting of the American Association for Cancer Research (AACR) has something for everyone involved in cancer research. It’s a veritable smorgasbord and just like watching TV there are multiple channels simultaneously going on over several days.

In this post we’ve taken a look at some of the NK cell presentations at AACR22 which caught our attention and why. You can find all of our ongoing AACR22 coverage here.

BSB subscribers can read our latest commentary – you can either log-in or click to access.

This content is restricted to subscribers

Posted by